Vol. 6 No. 4 (2026): April
Reimbursement Reviews

Garadacimab (Andembry)

decorative image of the issue cover

Published April 22, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses garadacimab (Andembry), solution for injection 200 mg per 1.2 mL single-dose prefilled syringe and single-dose prefilled pens, SC.
  • Indication: For routine prevention of attacks of hereditary angioedema in adult and pediatric patients (aged 12 years and older).